Bernadette Connaughton

Bernadette Mary Connaughton 0165

Board member

Elected to the Board in 2019 and regarded as an independent board member.

  • Member of the Audit Committee

Special competencies

More than 30 years of global strategic, commercial and leadership expertise, and a broad perspective on the strategy, capabilities and governance required for successful execution in U.S. and international markets.

Current Positions

Board member of Halozyme Therapeutics Inc. and Editas Medicine.

Share profile